Patents by Inventor DANIEL HASSAN

DANIEL HASSAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11924040
    Abstract: A system and a method for traffic management on a network. The method including: determining a desired intent for a network operator's traffic; determining a set of classes for a traffic flow through a link; determining a minimum and target bandwidth for each class in the set of class based on the desired intent; measure user score and bandwidth use for each class; allocate a bandwidth per class based on the minimum and target bandwidth and measured user score; and shape the traffic flow to the allocated bandwidth.
    Type: Grant
    Filed: August 16, 2021
    Date of Patent: March 5, 2024
    Inventors: Kamakshi Sridhar, Lars Anton Gunnarsson, Mostafa Mohamed Hassan, Alexander Havang, Matthew Lee Farmer, Roberto Lucarelli, Mark Daniel Yamada, Peter Thomas Salanki, Kenneth David Faiczak
  • Patent number: 11779547
    Abstract: An L-menthol pharmaceutical dosage form includes an effective amount of L-menthol for treating a gastrointestinal disorder. The L-menthol is within a plurality of particulates having a core and an enteric coating over the core. The core includes an L-menthol source that is at least 80% pure L-menthol. The dosage form may be used to treat gastrointestinal disorders, such as irritable bowel syndrome.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: October 10, 2023
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Syed M. Shah, Daniel Hassan
  • Patent number: 11723862
    Abstract: A composition comprises a therapeutically effective oral pharmaceutical dosage form. The dosage form includes an aqueous carrier material having an acidic pH and a plurality of individual pellets having a first dose of melatonin therein. The individual pellets comprises (i) a solid core; (ii) an active coating over the solid core, the active coating including melatonin and a hydrophilic binder; and (iii) an enteric coating over the active coating. A dissolution pH of the enteric coating is higher than the acidic pH of the aqueous carrier material.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: August 15, 2023
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Syed M. Shah, Daniel Hassan
  • Patent number: 11701425
    Abstract: A valerian composition includes valerian and an acidifying agent blended together in a pharmaceutically acceptable hydrogel-forming polymer matrix. An expedited release portion of the dosage form includes 5% to 50% of the valerian and is effective to release the valerian therein within 2 hours from placement in a 0.1 N HCl solution. A sustained release portion of the dosage form includes the remainder of the valerian and is effective to release the valerian therein within 10 hours from placement in a phosphate buffer with a pH of 6.8.
    Type: Grant
    Filed: September 8, 2021
    Date of Patent: July 18, 2023
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Syed M. Shah, Christopher Diorio, Daniel Hassan, Fred Hassan
  • Publication number: 20230045118
    Abstract: A composition comprises a therapeutically effective oral pharmaceutical dosage form. The dosage form includes an aqueous carrier material having an acidic pH and a plurality of individual pellets having a first dose of melatonin therein. The individual pellets comprises (i) a solid core; (ii) an active coating over the solid core, the active coating including melatonin and a hydrophilic binder; and (iii) an enteric coating over the active coating. A dissolution pH of the enteric coating is higher than the acidic pH of the aqueous carrier material.
    Type: Application
    Filed: January 15, 2021
    Publication date: February 9, 2023
    Inventors: SYED M. SHAH, DANIEL HASSAN
  • Patent number: 11389428
    Abstract: An oral melatonin pharmaceutical dosage form that contains a sustained release dose of melatonin includes melatonin and an acid dispersed in a hydrogel-forming polymer matrix that combine after ingestion to form an acidic hydrogel containing the melatonin.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: July 19, 2022
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Syed M. Shah, Daniel Hassan
  • Publication number: 20220079921
    Abstract: A melatonin composition has a dry granulation including a melatonin powder with a median melatonin particle size of 5 ?m to 40 ?m, a carboxylic acid powder, and a powder of a hydrogel-forming polymer. The dry granulation is combined with pharmaceutical excipients in a dry orally ingestible pharmaceutical dosage form adapted to absorb water upon ingestion and form a hydrogel including soluble melatonin and soluble carboxylic acid in the hydrogel, the carboxylic acid being in an amount sufficient to impart a pH of 4.4 or less to the hydrogel after ingestion.
    Type: Application
    Filed: January 17, 2020
    Publication date: March 17, 2022
    Inventors: Syed M. Shah, Daniel Hassan
  • Patent number: 11224658
    Abstract: A composition includes a pharmaceutical dosage form configured to disintegrate in oral saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein, the dosage form including a therapeutically effective amount of melatonin in a polymer carrier matrix and a sufficient amount of acid to impart the pH to the saliva, the amount of disintegrant being sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: January 18, 2022
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan, Patrick Corsino
  • Patent number: 11224657
    Abstract: A composition includes a pharmaceutical tablet dosage form configured to disintegrate in oral saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein, the dosage form including a therapeutically effective amount of melatonin in a carrier matrix, a disintegrant, and a sufficient amount of acid to impart the pH to the saliva, the amount of disintegrant being sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: January 18, 2022
    Assignee: Société des Produits Nestlé S. A.
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan, Patrick Corsino
  • Publication number: 20210401990
    Abstract: A valerian composition includes valerian and an acidifying agent blended together in a pharmaceutically acceptable hydrogel-forming polymer matrix. An expedited release portion of the dosage form includes 5% to 50% of the valerian and is effective to release the valerian therein within 2 hours from placement in a 0.1 N HCl solution. A sustained release portion of the dosage form includes the remainder of the valerian and is effective to release the valerian therein within 10 hours from placement in a phosphate buffer with a pH of 6.8.
    Type: Application
    Filed: September 8, 2021
    Publication date: December 30, 2021
    Inventors: Syed M. Shah, Christopher Diorio, Daniel Hassan, Fred Hassan
  • Patent number: 11208247
    Abstract: Melatonin tablets with a high concentration of citric acid are packaged in a blister package that enhances storage stability. Such a packaging material includes a blister film forming a cavity holding the tablet therein. The blister film includes a polyvinyl chloride (PVC) film having a thickness of 180 ?m to 270 ?m coated with a polyvinylidene chloride (PVDC) coating having a coating weight of 110 g/m2 to 130 g/m2. An aluminum foil lid closes the cavity and encapsulates the tablet within the blister film and lid. The lid has a thickness of 20 ?m to 30 ?m.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: December 28, 2021
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan
  • Patent number: 11207276
    Abstract: A pharmaceutical dosage form includes an effective amount of L-menthol for treating a gastrointestinal disorder. The L-menthol is within a plurality of particulates having a core including crystalline L-menthol dissolved in a terpene-based essential oil. A proteinaceous coating of a continuous film of proteinaceous material is over the core.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: December 28, 2021
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Syed M. Shah, Fred Hassan, Daniel Hassan, Sarah Hassan
  • Patent number: 11141485
    Abstract: A valerian composition includes a therapeutically effective pharmaceutical dosage form having a solid core including a polymer in which valerian and a valerian stability improving amount of an acidifying agent are contained. The valerian stability improving amount of acidifying agent being sufficient to impart a pH of 2 to 5 to the polymer.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: October 12, 2021
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Syed M. Shah, Christopher Diorio, Daniel Hassan, Fred Hassan
  • Patent number: 11141484
    Abstract: A valerian composition includes a therapeutically effective pharmaceutical dosage form having a solid core including a polymer in which valerian and a valerian stability improving amount of an acidifying agent are contained. The valerian stability improving amount of acidifying agent being sufficient to impart a pH of 2 to 5 to the polymer.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: October 12, 2021
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Syed M. Shah, Christopher Diorio, Daniel Hassan, Fred Hassan
  • Publication number: 20210220264
    Abstract: A composition comprises a therapeutically effective oral pharmaceutical dosage form. The dosage form includes an aqueous carrier material having an acidic pH and a plurality of individual pellets having a first dose of melatonin therein. The individual pellets comprises (i) a solid core; (ii) an active coating over the solid core, the active coating including melatonin and a hydrophilic binder; and (iii) an enteric coating over the active coating. A dissolution pH of the enteric coating is higher than the acidic pH of the aqueous carrier material.
    Type: Application
    Filed: January 15, 2021
    Publication date: July 22, 2021
    Inventors: Syed M. Shah, Daniel Hassan
  • Patent number: 10960075
    Abstract: A composition includes an oral thin film pharmaceutical dosage form configured to disintegrate in saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein. The dosage form includes a therapeutically effective amount of melatonin in a polymer carrier matrix and a sufficient amount of acid to impart the pH to the saliva. The dosage can completely disintegrate in the saliva within ten minutes from contacting the saliva.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: March 30, 2021
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan, Patrick Corsino
  • Patent number: 10888522
    Abstract: Controlled-release therapeutic compositions including melatonin combined with sedative and/or analgesic ingredients are described. The compositions have a solid core including melatonin in an acidified polymeric matrix. A sedative ingredient such as GABA receptor agonist may also be in the acidified polymeric matrix. The composition may include an expedited release portion providing a burst release of active ingredients and a sustained release portion providing a sustained release of active ingredients.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: January 12, 2021
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Syed M. Shah, Daniel Hassan, Christopher Diorio, Fred Hassan
  • Publication number: 20200383949
    Abstract: An oral melatonin pharmaceutical dosage form that contains a sustained release dose of melatonin includes melatonin and an acid dispersed in a hydrogel-forming polymer matrix that combine after ingestion to form an acidic hydrogel containing the melatonin.
    Type: Application
    Filed: August 25, 2020
    Publication date: December 10, 2020
    Inventors: Syed M. Shah, Daniel Hassan
  • Publication number: 20200268886
    Abstract: A composition includes a pharmaceutical tablet dosage form configured to disintegrate in oral saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein, the dosage form including a therapeutically effective amount of melatonin in a carrier matrix, a disintegrant, and a sufficient amount of acid to impart the pH to the saliva, the amount of disintegrant being sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.
    Type: Application
    Filed: May 13, 2020
    Publication date: August 27, 2020
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan, Patrick Corsino
  • Patent number: D907760
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: January 12, 2021
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Daniel Hassan, Fred Hassan